ArticleBMC microbiology2026
Development and validation of a rapid triple-target gold nanoparticle lateral flow immunoassay for detection of three avian mycoplasmas immunochromatographic strip test for avian mycoplasma detection.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAvian mycoplasmas, including Mycoplasma gallisepticum (MG), Mycoplasma synoviae (MS), and Mycoplasma meleagridis (MM) are major pathogens of poultry causing respiratory and reproductive disorders that result in considerable economic losses. The existing diagnostic methods such as culture, ELISA, and PCR are accurate and reliable but labour-intensive, costly, and impractical for routine field screening. This study aimed to develop a rapid and cost-effective colloidal gold-based immunochromatographic strip for the simultaneous serological detection of antibodies against MG, MS, and MM in poultry, reflecting exposure or infection status.
methodsRecombinant proteins pMGA (MG), VlhA (MS), and Mm19 (MM) were expressed in Escherichia coli, purified, and immobilized on nitrocellulose membranes as test lines. Monoclonal and polyclonal antibodies were conjugated to 20 nm gold nanoparticles and reaction parameters (pH, antibody concentration, conjugate ratio) were optimized. The diagnostic performance of the colloidal gold-based immunochromatographic strip was evaluated using a panel of well-characterized clinical samples. ELISA assays were used as the reference standard. The panel comprised samples confirmed positive for Mycoplasma infections as well as samples positive for other common avian infectious agents, to assess diagnostic sensitivity, specificity, and potential cross-reactivity.
resultsThe developed strip test reacted exclusively with MG, MS, and MM with no cross-reactivity to other avian Mycoplasma species or common respiratory pathogens. The visual detection limit was 31.25 ng/mL, with results obtained in 15 min without any specialized equipment. Compared to ELISA, the diagnostic sensitivity of the strip reached 96.7% (95% CI: 82.8-99.9%) and specificity 98% (95% CI: 89.4-99.9%), with excellent agreement (Cohen's κ = 0.96). The inter-assay coefficient of variation was < 8%, and strips retained full reactivity for at least 6 months upon storage at 4 °C.
conclusionsThis study presents the first validated multiplex serological platform for the simultaneous detection of antibodies against avian mycoplasmas. The developed triple-target immunochromatographic strip provides a rapid, accurate, and cost-effective tool for on-site serological screening of MG, MS, and MM infections. Its simplicity, rapid turnaround time, and reliability make it a promising alternative for large-scale surveillance and early monitoring programs in poultry health management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.